

Reliability Report Autumn 2021

IMPLANTABLE COCHLEAR STIMULATORS AND SOUND PROCESSORS

POWERFUL CONNECTIONS





START HERE

| Our Mission | 4 |
|--|----|
| Reporting on Reliability | 5 |
| Implantable Cochlear Stimulators | 6 |
| HiRes Ultra 3D (V2) cochlear implant | 8 |
| HiRes Ultra (V2) cochlear implant | 10 |
| HiRes Ultra 3D (V1) cochlear implant | 12 |
| HiRes Ultra (V1) cochlear implant | 14 |
| HiRes 90K Advantage cochlear implant | 16 |
| HiRes 90K cochlear implant | 18 |
| CII Bionic Ear cochlear implant | 26 |
| Clarion 1.2 cochlear implant | 28 |
| Clarion 1.0 cochlear implant | 30 |
| Sound Processor Stimulators | 32 |
| Naída CI M and Sky CI M sound processors | 33 |
| Naída CI Q90 sound processor | 34 |
| Chorus sound processor | 34 |
| Neptune sound processor | 35 |
| Harmony sound processor | 35 |
| Appendix | 36 |

OUR MISSION

At Advanced Bionics, we are dedicated to improving lives by developing implantable technologies and services that help our recipients achieve their full potential.

Our commitment to putting patients first and providing the best possible hearing performance remains at the forefront of all that we do. The trust patients place in us inspires us to act with integrity and transparency as we strive for excellence each and every day in all that we do.

This reliability report is an example of our commitment to an open and transparent communication to you.

REPORTING ON RELIABILITY

Advanced Bionics remains dedicated to transparency and accuracy in reliability reporting.

To ensure that patients and professionals globally understand Advanced Bionics product performance, AB reports reliability data for each type, and significant variant of that type, of Cochlear Implant Stimulators (commonly referred to as implants) semi-annually.

Reporting utilizes methodologies recommended by both the International Organization for Standardization in **ISO 5841-2:2014**¹, the principles outlined in the European Consensus on Cochlear Implant Failures and Explanations²; and **ANSI/AAMI CI86** - Cochlear Implant Systems: Requirements for Safety, Functional Verification, Labeling and Reliability Reporting³.

For each type of implant, the number of recipients and the Cumulative Survival Rate (CSR) is shared. The number of recipients using each implant is displayed as a table detailing adults and children, as well as a combination of both, in accordance with ISO 5841-2:2014 and ANSI/AAMI CI86. Separate graphs for each reporting standard exhibit the CSR.

Reliability of each currently-available sound processor is also reported utilizing methodologies that meet the recommendations of ANSI/AAMI CI86 - Cochlear Implant Systems: Requirements for Safety, Functional Verification, Labeling and Reliability Reporting³.

- 1. ISO 5841-2 (2014) Implants for Surgery Cardiac Pacemakers. International Organization for Standardization (ISO), Geneva, Switzerland.
- 2. European Consensus Statement on Cochlear Implant Failures and Explanations. (2005) Otology and Neurology, 26(6): 1097-1099.
- 3. ANSI/AAMI Cl86. Cochlear Implant Systems: Requirements for Safety, Functional Verification, Labeling and Reliability Reporting. (2017). Arlington, VA: American National Standards Institute.

INTERPRETING TABLES AND GRAPHS

IMPLANTABLE COCHLEAR STIMULATORS

Number of registered HiRes 90K Advantage implants

As of September 30, 2021 Date of first commercial introduction^a: 2012


 STANDARD
 ADULTS
 CHILDREN
 COMBINED

 ISO 5841-2:2014
 15341
 20190
 37587^b


 ANSI/AAMI CI86
 19465°
 18122
 37587

Number of registered users is detailed for adults, children and a combination of all ages in accordance with reporting methodologies.

- a. Dates provided are those for major markets covered by FDA and TUV regulation. Some implants may be pending approval in a subset of additional regions.
- b. The combined number also includes any registered users for whom we do not have date of birth information.
- c. The adult number also includes users whose personal information is not available or may not be obtainable due to certain privacy laws in certain countries.



CUMULATIVE SURVIVAL PERCENTAGE Detailed CSR percentages are **ADULTS** 99.93% 99.91% 99.85% 99.81% 99.78% 99.74% 99.71% 99.74% the table. Results are COMBINED 99.87% 99.78% 99.67% 99.58% 99 52% 99.44% 99.37% 99.34% broken up into adults, children, and shown CHILDREN 99.80% 99.67% 99.49% 99.35% 99.25% 99.11% 98.96% 98.92% as a combined total.



The ANSI/AAMI CI86 Standard requires that all removed devices are classified into three categories, namely those related to device failure, to medical reasons for explant, or those whose reason for explant cannot be determined.

COMBINED ADULT AND CHILDREN Total Inconclusive Device CRP Medical CRP Total All Categories CRP CI Up CI Down Detailed CRP values are 0.88% 0.73% 0.13% 0.02% 0.98% 0.79% shown for each year in the table. Results are broken 2 1.13% 0.23% 0.04% 1.40% 1 52% 1.28% 1.41% 0.35% 0.04% 1.94% up into adults, children, and 3 1.80% 1.66% 4 1.66% 0.45% 0.07% 2.16% 2.32% 2.01% shown as a combined total. 1.82% 0.51% 0.10% 2.58% 2.25% 2.42% 6 1.98% 0.59% 0.11% 2.67% 2.85% 2.49% 2.13% 2.72% 0.68% 0.12% 2.92% 3.12% 8 2 26% 0.75% 0.12% 3.12% 3.34% 2.89%

Throughout the report, we will present the data and graphs to represent the conditions for: all analysis categories combined; by analysis category for adults and children; removal rates by analysis category for adults; and removal rates by analysis category for children.

CURRENT-GENERATION IMPLANT DATA

HIRES ULTRA 3D V2

The HiRes™ Ultra 3D (V2) cochlear implant is an update to the previous HiRes Ultra 3D (V1) device. It includes reliability improvements resulting from the Corrective and Preventive Action undertaken by Advanced Bionics related to returned devices showing a common failure mode of fluid ingress into the external electrode pocket.

Based off the standard HiRes Ultra platform but featuring an innovative multi-magnet assembly, the HiRes Ultra 3D implant allows the use of clinical MRI at 1.5T and 3T without the need for magnet removal or head-bandaging. Due to the low torque, the user can be expected to have a hassle free and pain free experience.

The HiRes Ultra 3D (V2) device has now competed a 1.5-year reliability data, and the Cumulative Survival Rate (CSR) is 99.97%.




Number of registered HiRes Ultra 3D (V2) implants

As of September 30, 2021

Date of first commercial introduction^a: 2019

| STANDARD | ADULTS | CHILDREN | COMBINED |
|-----------------|--------|----------|-------------------|
| ISO 5841-2:2014 | 4476 | 1834 | 6644 ^b |
| ANSI/AAMI CI86 | 5128° | 1517 | 6645 |

ISO 5841-2:2014



| Years in use | 1 | 1.5 |
|--------------|---------|------------------|
| ADULTS | 100.00% | 100.00% |
| COMBINED | 99.97% | 99.97% |
| CHILDREN | 99.88% | N/A ^d |

- a. Dates provided are those for major markets covered by FDA and TUV regulation. Some implants may be pending approval in a subset of additional regions.
- b. The combined number also includes any registered users for whom we do not have date of birth information.
- c. The adult number also includes users whose personal information is not available or may not be obtainable due to certain privacy laws in certain countries.
- d. Sample size for children at 1.5 years is not large enough for reporting.




REMOVAL RATES ANALYSIS FOR ALL ANALYSIS CATEGORIES AND DIFFERENT PATIENTS POPULATION







REMOVAL RATES ANALYSIS CATEGORIES FOR ADULTS AND CHILDREN



COMBINED ADULTS AND CHILDREN

| Voor | Year Medical CRP | P Device CRP Inconclusive CRP | Total All Categories | Total | | |
|------|------------------|-------------------------------|----------------------|----------------------|-------|---------|
| real | Medical Chr | Device Chr | Inconclusive Chr | Total All Categories | CI Up | CI Down |
| 1 | 0.59% | 0.03% | 0.00% | 0.63% | 0.85% | 0.40% |
| 1.5 | 0.63% | 0.03% | 0.00% | 0.63% | 0.85% | 0.40% |

HIRES ULTRA V2

The HiRes™ Ultra (V2) cochlear implant has the same reliability improvements as the HiRes Ultra 3D (V2) device.

Featuring the proven performance platform as the HiRes 90K[™] Advantage, the HiRes Ultra (V2) offers a robust, thin, and discreet mechanical design that is suitable for adults and children.



The HiRes Ultra (V2) device has a limited number of devices that have completed the 1-year data point and the data presented may not reach statistical significance. There has not been a confirmed device-related failure to date.

Number of registered HiRes Ultra (V2) implants

As of September 30, 2021

Date of first commercial introduction^a: 2019

| STANDARD | ADULTS | CHILDREN | COMBINED |
|-----------------|--------|----------|-------------------|
| ISO 5841-2:2014 | 266 | 776 | 1312 ^b |
| ANSI/AAMI CI86 | 585° | 727 | 1312 |

- a. Dates provided are those for major markets covered by FDA and TUV regulation. Some implants may be pending approval in a subset of additional regions.
- b. The combined number also includes any registered users for whom we do not have date of birth information.
- c. The adult number also includes users whose personal information is not available or may not be obtainable due to certain privacy laws in certain countries.

ISO 5841-2:2014



| Years in use | |
|--------------|---------|
| ADULTS | 100.00% |
| COMBINED | 100.00% |
| CHILDREN | 100.00% |



COMBINED ADULTS AND CHILDREN

1.50%

1.00%

0.50%

0.00%

1.50%

1.00%

0.50%

0.00%

| Year | Medical CRP Device CRP Inconclusive CRP Total All Categories | Total All Catagorias | To | otal | | |
|------|--|----------------------|------------------|----------------------|-------|---------|
| Teal | Wedical Chr | Device Onr | Inconclusive Chr | Total All Categories | CI Up | CI Down |
| 1 | 0.25% | 0.00% | 0.00% | 0.25% | 0.54% | 0.00% |

PREVIOUS-GENERATION IMPLANT DATA

HIRES ULTRA 3D V1

The HiResTM Ultra 3D (V1) cochlear implant was subject to a Voluntary Field Action initiated by Advanced Bionics on February 18, 2020, and was withdrawn from sale worldwide. The Voluntary Field Action was due to recognition of a common failure mode for a small number of devices, resulting in loss of clinical benefit. Advanced Bionics will continue to provide regular reliability updates on the HiRes Ultra platform as new data and information becomes available.

Number of registered HiRes Ultra 3D (V1) implants


As of September 30, 2021

Last year of distributiona: subject to voluntary field action February 18, 2020

| STANDARD | ADULTS | CHILDREN | COMBINED |
|-----------------|--------|----------|-------------------|
| ISO 5841-2:2014 | 4545 | 1583 | 6371 ^b |
| ANSI/AAMI CI86 | 5022° | 1349 | 6371 |

- a. Dates provided are those for major markets covered by FDA and TUV regulation. Some implants may be pending approval in a subset of additional regions.
- b. The combined number also includes any registered users for whom we do not have date of birth information.
- c. The adult number also includes users whose personal information is not available or may not be obtainable due to certain privacy laws in certain countries.

ISO 5841-2:2014



| Years in use | | 1.5 | | 2.5 |
|--------------|--------|--------|--------|--------|
| ADULTS | 99.84% | 99.38% | 98.20% | 96.55% |
| COMBINED | 99.78% | 99.08% | 97.48% | 95.38% |
| CHILDREN | 99.55% | 98.08% | 95.02% | 91.27% |



12.00%

9.00%

6.00%

3.00%

0.00%



12.00%

9.00%

6.00%

3.00%

0.00%

| Year | Year Medical CRP | RP Device CRP Inconclusive CRP | Total All Categories | Total | | |
|------|------------------|--------------------------------|----------------------|----------------------|-------|---------|
| leai | Medical Chr | Device Chr | Inconclusive Chr | Total All Categories | CI Up | CI Down |
| 1 | 0.96% | 0.22% | 0.02% | 1.19% | 1.46% | 0.93% |
| 2 | 1.62% | 2.56% | 0.06% | 4.19% | 4.70% | 3.68% |

HIRES ULTRA V1

The HiResTM Ultra (V1) cochlear implant was subject to a Voluntary Field Action initiated by Advanced Bionics on February 18, 2020, and was withdrawn from sale worldwide. This was due to recognition of a common failure mode for a small number of devices, resulting in loss of clinical benefit. Advanced Bionics will continue to provide regular reliability updates on the HiRes Ultra platform as new data and information becomes available.

Number of registered HiRes Ultra (V1) implants


As of September 30, 2021

Last year of distribution^a: subject to voluntary field action February 18, 2020

| STANDARD | ADULTS | CHILDREN | COMBINED |
|-----------------|--------|----------|--------------------|
| ISO 5841-2:2014 | 7087 | 4273 | 12135 ^b |
| ANSI/AAMI CI86 | 8363° | 3765 | 12128 |

- a. Dates provided are those for major markets covered by FDA and TUV regulation. Some implants may be pending approval in a subset of additional regions.
- b. The combined number also includes any registered users for whom we do not have date of birth information.
- c. The adult number also includes users whose personal information is not available or may not be obtainable due to certain privacy laws in certain countries.


ISO 5841-2:2014



| Years in use | | | | |
|--------------|--------|--------|--------|--------|
| ADULTS | 99.97% | 99.56% | 97.13% | 92.15% |
| COMBINED | 99.95% | 99.42% | 96.45% | 89.98% |
| CHILDREN | 99.91% | 99.09% | 94.62% | 84.21% |




REMOVAL RATES ANALYSIS FOR ALL ANALYSIS CATEGORIES AND DIFFERENT PATIENTS POPULATION






REMOVAL RATES ANALYSIS CATEGORIES FOR CHILDREN

REMOVAL RATES ANALYSIS CATEGORIES FOR ADULTS AND CHILDREN





COMBINED ADULTS AND CHILDREN

| Voor | Medical CRP | Device CRP | Inconclusive CRP | Total All Catagorica | Total | | | |
|------|-------------|------------|------------------|----------------------|--------|---------|--|--|
| Year | wedical CRP | Device CRP | inconclusive CRP | Total All Categories | CI Up | CI Down | | |
| 1 | 0.69% | 0.05% | 0.02% | 0.76% | 0.91% | 0.60% | | |
| 2 | 1.10% | 0.59% | 0.03% | 1.71% | 1.94% | 1.47% | | |
| 3 | 1.43% | 3.65% | 0.08% | 5.10% | 5.53% | 4.67% | | |
| 4 | 1.86% | 10.28% | 0.11% | 12.04% | 12.85% | 11.24% | | |

HIRES 90K ADVANTAGE

The HiRes 90K[™] Advantage cochlear implant offers mechanical improvements over its predecessor, the HiRes 90K cochlear implant. It has the capability to offer advanced sound coding strategies, together with the security of a deep bone bed.

Number of registered HiRes 90K Advantage implants

As of September 30, 2021


Date of first commercial introduction^a: 2012. Still available in selected markets

| STANDARD | ADULTS | CHILDREN | COMBINED |
|-----------------|--------|----------|--------------------|
| ISO 5841-2:2014 | 15341 | 20190 | 37587 ^b |
| ANSI/AAMI CI86 | 19465° | 18122 | 37587 |




- a. Dates provided are those for major markets covered by FDA and TUV regulation. Some implants may be pending approval in a subset of additional regions.
- b. The combined number also includes any registered users for whom we do not have date of birth information.
- c. The adult number also includes users whose personal information is not available or may not be obtainable due to certain privacy laws in certain countries.

ISO 5841-2:2014




| Years in use | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 |
|--------------|--------|--------|--------|--------|--------|--------|--------|--------|
| ADULTS | 99.93% | 99.91% | 99.85% | 99.81% | 99.78% | 99.74% | 99.74% | 99.71% |
| COMBINED | 99.87% | 99.78% | 99.67% | 99.58% | 99.52% | 99.44% | 99.37% | 99.34% |
| CHILDREN | 99.80% | 99.67% | 99.49% | 99.35% | 99.25% | 99.11% | 98.96% | 98.92% |

REMOVAL RATES ANALYSIS FOR ALL ANALYSIS CATEGORIES



REMOVAL RATES ANALYSIS CATEGORIES



COMBINED ADULT AND CHILDREN

| Year | Medical CRP | Device CRP | Inconclusive CRP | Total All Categories | To | otal |
|------|-------------|------------|------------------|----------------------|-------|---------|
| ieai | Medical Chr | Device Chr | Inconclusive Chr | Total All Categories | CI Up | CI Down |
| 1 | 0.73% | 0.13% | 0.02% | 0.88% | 0.98% | 0.79% |
| 2 | 1.13% | 0.23% | 0.04% | 1.40% | 1.52% | 1.28% |
| 3 | 1.41% | 0.35% | 0.04% | 1.80% | 1.94% | 1.66% |
| 4 | 1.66% | 0.45% | 0.07% | 2.16% | 2.32% | 2.01% |
| 5 | 1.82% | 0.51% | 0.10% | 2.42% | 2.58% | 2.25% |
| 6 | 1.98% | 0.59% | 0.11% | 2.67% | 2.85% | 2.49% |
| 7 | 2.13% | 0.68% | 0.12% | 2.92% | 3.12% | 2.72% |
| 8 | 2.26% | 0.75% | 0.12% | 3.12% | 3.34% | 2.89% |
| | | | | | | |

HIRES 90K vendor A post-mod

The HiRes 90KTM cochlear implant offers access to advanced sound coding technologies. It has undergone manufacturing modifications, with the version currently available being designated as the HiRes 90K (vendor A post-mod) implant.

Number of registered HiRes 90K implants (vendor A post-mod)

As of September 30, 2021


Last year of distribution^a. Still available in selected markets.

| STANDARD | ADULTS | CHILDREN | COMBINED |
|-----------------|--------|----------|--------------------|
| ISO 5841-2:2014 | 31468 | 44781 | 78785 ^b |
| ANSI/AAMI CI86 | 39509° | 39366 | 78875 |




- a. Dates provided are those for major markets covered by FDA and TUV regulation. Some implants may be pending approval in a subset of additional regions.
- b. The combined number also includes any registered users for whom we do not have date of birth information.
- c. The adult number also includes users whose personal information is not available or may not be obtainable due to certain privacy laws in certain countries.


ISO 5841-2:2014



| Years in use | | | | | 5 | 6 | | | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 |
|--------------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|
| ADULTS | 99.95% | 99.93% | 99.89% | 99.83% | 99.79% | 99.73% | 99.72% | 99.69% | 99.65% | 99.58% | 99.52% | 99.51% | 99.51% | 99.51% | 99.51% | 99.42% |
| COMBINED | 99.88% | 99.75% | 99.61% | 99.46% | 99.35% | 99.25% | 99.19% | 99.10% | 99.05% | 98.94% | 98.90% | 98.86% | 98.85% | 98.83% | 98.81% | 98.61% |
| CHILDREN | 99.82% | 99.61% | 99.39% | 99.17% | 98.99% | 98.85% | 98.75% | 98.62% | 98.55% | 98.41% | 98.38% | 98.32% | 98.29% | 98.25% | 98.20% | 97.88% |









1.00%

0.00%


REMOVAL RATES ANALYSIS FOR ALL ANALYSIS CATEGORIES AND DIFFERENT PATIENTS POPULATION



REMOVAL RATES ANALYSIS CATEGORIES FOR CHILDREN



REMOVAL RATES ANALYSIS CATEGORIES FOR ADULTS AND CHILDREN



COMBINED ADULTS AND CHILDREN

| Voor | Medical CRP | Davisa CDD | Inconclusive CRP | Total All Catagorias | To | otal |
|------|-------------|------------|------------------|----------------------|-------|---------|
| Year | Medical CRP | Device CRP | inconclusive CRP | Total All Categories | CI Up | CI Down |
| 1 | 0.81% | 0.14% | 0.02% | 0.96% | 1.03% | 0.90% |
| 2 | 1.23% | 0.29% | 0.04% | 1.55% | 1.64% | 1.47% |
| 3 | 1.52% | 0.45% | 0.06% | 2.02% | 2.12% | 1.92% |
| 4 | 1.76% | 0.61% | 0.08% | 2.45% | 2.56% | 2.34% |
| 5 | 1.95% | 0.73% | 0.11% | 2.78% | 2.90% | 2.66% |
| 6 | 2.10% | 0.85% | 0.13% | 3.06% | 3.18% | 2.93% |
| 7 | 2.23% | 0.92% | 0.14% | 3.27% | 3.40% | 3.14% |
| 8 | 2.36% | 1.03% | 0.15% | 3.51% | 3.65% | 3.37% |
| 9 | 2.46% | 1.10% | 0.16% | 3.69% | 3.84% | 3.54% |
| 10 | 2.63% | 1.21% | 0.19% | 3.98% | 4.14% | 3.82% |
| 11 | 2.71% | 1.25% | 0.20% | 4.11% | 4.28% | 3.95% |
| 12 | 2.86% | 1.29% | 0.21% | 4.31% | 4.49% | 4.14% |
| 13 | 3.00% | 1.32% | 0.22% | 4.49% | 4.67% | 4.30% |
| 14 | 3.11% | 1.33% | 0.24% | 4.62% | 4.83% | 4.42% |
| 15 | 3.20% | 1.39% | 0.26% | 4.79% | 5.01% | 4.56% |
| 16 | 3.30% | 1.54% | 0.31% | 5.08% | 5.40% | 4.75% |

HIRES 90K vendor A all

Number of registered HiRes 90K implants (vendor A all)


As of September 30, 2021

Last year of distribution^a. Still available in selected markets.

| STANDARD | ADULTS | CHILDREN | COMBINED |
|-----------------|--------|----------|--------------------|
| ISO 5841-2:2014 | 33016 | 45944 | 81596 ^b |
| ANSI/AAMI CI86 | 41270° | 40326 | 81596 |

- a. Dates provided are those for major markets covered by FDA and TUV regulation. Some implants may be pending approval in a subset of additional regions.
- b. The combined number also includes any registered users for whom we do not have date of birth information.
- c. The adult number also includes users whose personal information is not available or may not be obtainable due to certain privacy laws in certain countries.


ISO 5841-2:2014




| Years in use | | | | | 5 | 6 | | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 |
|--------------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|
| ADULTS | 99.93% | 99.90% | 99.86% | 99.77% | 99.74% | 99.65% | 99.64% | 99.57% | 99.49% | 99.40% | 99.30% | 99.24% | 99.22% | 99.14% | 99.07% | 98.95% | 98.88% | 98.74% |
| COMBINED | 99.87% | 99.73% | 99.59% | 99.43% | 99.30% | 99.19% | 99.12% | 98.99% | 98.90% | 98.78% | 98.70% | 98.60% | 98.56% | 98.45% | 98.36% | 98.18% | 98.06% | 97.89% |
| CHILDREN | 99.82% | 99.59% | 99.37% | 99.14% | 98.95% | 98.79% | 98.68% | 98.50% | 98.40% | 98.25% | 98.19% | 98.06% | 97.98% | 97.84% | 97.72% | 97.46% | 97.27% | 97.05% |




REMOVAL RATES ANALYSIS FOR ALL ANALYSIS CATEGORIES AND DIFFERENT PATIENTS POPULATION






REMOVAL RATES ANALYSIS CATEGORIES FOR CHILDREN

REMOVAL RATES ANALYSIS CATEGORIES FOR ADULTS AND CHILDREN





COMBINED ADULTS AND CHILDREN

| Year | Medical CRP | Device CRP | Inconclusive CRP | Total All Catagorias | To | otal |
|------|-------------|------------|------------------|----------------------|-------|---------|
| rear | Medical CRP | Device CRP | Inconclusive CRP | Total All Categories | CI Up | CI Down |
| 1 | 0.81% | 0.15% | 0.02% | 0.98% | 1.05% | 0.91% |
| 2 | 1.23% | 0.31% | 0.05% | 1.58% | 1.67% | 1.49% |
| 3 | 1.52% | 0.48% | 0.07% | 2.06% | 2.16% | 1.96% |
| 4 | 1.77% | 0.67% | 0.10% | 2.52% | 2.63% | 2.41% |
| 5 | 1.96% | 0.80% | 0.12% | 2.86% | 2.98% | 2.75% |
| 6 | 2.10% | 0.94% | 0.14% | 3.16% | 3.29% | 3.04% |
| 7 | 2.25% | 1.03% | 0.16% | 3.41% | 3.54% | 3.28% |
| 8 | 2.38% | 1.17% | 0.17% | 3.69% | 3.83% | 3.55% |
| 9 | 2.47% | 1.28% | 0.18% | 3.90% | 4.05% | 3.75% |
| 10 | 2.64% | 1.41% | 0.21% | 4.21% | 4.37% | 4.05% |
| 11 | 2.73% | 1.49% | 0.22% | 4.40% | 4.57% | 4.23% |
| 12 | 2.88% | 1.60% | 0.24% | 4.66% | 4.84% | 4.48% |
| 13 | 3.01% | 1.66% | 0.25% | 4.85% | 5.05% | 4.66% |
| 14 | 3.13% | 1.78% | 0.27% | 5.11% | 5.32% | 4.90% |
| 15 | 3.22% | 1.91% | 0.28% | 5.34% | 5.57% | 5.10% |
| 16 | 3.29% | 2.07% | 0.30% | 5.58% | 5.85% | 5.30% |
| 17 | 3.33% | 2.23% | 0.34% | 5.81% | 6.14% | 5.48% |
| 18 | 3.33% | 2.40% | 0.34% | 5.97% | 6.38% | 5.57% |

HIRES 90K vendor A pre-mod


Number of registered HiRes 90K implants (vendor A pre-mod)

As of September 30, 2021 Last year of distribution^a: 2005.

| STANDARD | ADULTS | CHILDREN | COMBINED |
|-----------------|--------|----------|-------------------|
| ISO 5841-2:2014 | 1548 | 1163 | 2721 ^b |
| ANSI/AAMI CI86 | 1661° | 894 | 2555 |


- a. Dates provided are those for major markets covered by FDA and TUV regulation. Some implants may be pending approval in a subset of additional regions.
- b. The combined number also includes any registered users for whom we do not have date of birth information.
- c. The adult number also includes users whose personal information is not available or may not be obtainable due to certain privacy laws in certain countries.

ISO 5841-2:2014



| Years in use | | | | | 5 | 6 | | 8 | 9 | 10 | -11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 |
|--------------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|
| ADULTS | 99.61% | 99.35% | 99.15% | 98.69% | 98.56% | 98.22% | 98.09% | 97.68% | 97.14% | 96.87% | 96.46% | 96.05% | 95.92% | 95.57% | 95.37% | 95.23% | 95.15% | 95.01% |
| COMBINED | 99.56% | 99.22% | 98.92% | 98.39% | 98.09% | 97.66% | 97.36% | 96.70% | 96.16% | 95.89% | 95.46% | 94.91% | 94.68% | 94.24% | 94.01% | 93.85% | 93.71% | 93.55% |
| CHILDREN | 99.48% | 99.04% | 98.60% | 97.98% | 97.44% | 96.90% | 96.35% | 95.35% | 94.80% | 94.52% | 94.15% | 93.41% | 93.04% | 92.48% | 92.20% | 92.02% | 91.80% | 91.59% |

REMOVAL RATES ANALYSIS CATEGORIES FOR ADULTS




7.50%

5.00%

2.50%

0.00%


REMOVAL RATES ANALYSIS FOR ALL ANALYSIS CATEGORIES AND DIFFERENT PATIENTS POPULATION




REMOVAL RATES ANALYSIS CATEGORIES FOR CHILDREN

13

15



REMOVAL RATES ANALYSIS CATEGORIES FOR ADULTS AND CHILDREN



COMBINED ADULTS AND CHILDREN

| Year | Medical CRP | Device CRP | Inconclusive CRP | Total All Catagorias | Total | | | |
|------|-------------|------------|------------------|----------------------|--------|---------|--|--|
| rear | Medical CRP | Device CRP | Inconclusive CRP | Total All Categories | CI Up | CI Down | | |
| 1 | 0.88% | 0.52% | 0.00% | 1.40% | 1.84% | 0.96% | | |
| 2 | 1.18% | 0.96% | 0.19% | 2.32% | 2.88% | 1.75% | | |
| 3 | 1.56% | 1.38% | 0.38% | 3.28% | 3.95% | 2.61% | | |
| 4 | 1.93% | 2.17% | 0.41% | 4.46% | 5.23% | 3.68% | | |
| 5 | 2.05% | 2.70% | 0.49% | 5.16% | 5.99% | 4.33% | | |
| 6 | 2.20% | 3.23% | 0.57% | 5.90% | 6.78% | 5.01% | | |
| 7 | 2.51% | 3.65% | 0.69% | 6.71% | 7.65% | 5.77% | | |
| 8 | 2.74% | 4.34% | 0.69% | 7.60% | 8.60% | 6.60% | | |
| 9 | 2.78% | 4.87% | 0.69% | 8.15% | 9.18% | 7.12% | | |
| 10 | 2.90% | 5.26% | 0.77% | 8.71% | 9.77% | 7.65% | | |
| 11 | 3.10% | 5.64% | 0.81% | 9.30% | 10.40% | 8.21% | | |
| 12 | 3.25% | 6.22% | 0.81% | 10.01% | 11.14% | 8.88% | | |
| 13 | 3.29% | 6.49% | 0.85% | 10.34% | 11.49% | 9.19% | | |
| 14 | 3.50% | 7.03% | 0.85% | 11.05% | 12.23% | 9.87% | | |
| 15 | 3.58% | 7.31% | 0.85% | 11.38% | 12.58% | 10.18% | | |
| 16 | 3.62% | 7.46% | 0.85% | 11.57% | 12.77% | 10.36% | | |
| 17 | 3.66% | 7.64% | 0.90% | 11.82% | 13.04% | 10.61% | | |
| 18 | 3.66% | 7.81% | 0.90% | 11.98% | 13.22% | 10.74% | | |

HIRES 90K vendor B

Number of registered HiRes 90K implants (vendor B)


As of September 30, 2021.

Last year of distribution^a. Subject to voluntary recall in 2006.

| STANDARD | ADULTS | CHILDREN | COMBINED |
|-----------------|--------|----------|-------------------|
| ISO 5841-2:2014 | 2204 | 1837 | 4065 ^b |
| ANSI/AAMI CI86 | 2561° | 1504 | 4065 |

- a. Dates provided are those for major markets covered by FDA and TUV regulation. Some implants may be pending approval in a subset of additional regions.
- b. The combined number also includes any registered users for whom we do not have date of birth information.
- c. The adult number also includes users whose personal information is not available or may not be obtainable due to certain privacy laws in certain countries.


ISO 5841-2:2014




| Years in use | | | | | 5 | 6 | | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 |
|--------------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|
| ADULTS | 97.89% | 91.83% | 87.54% | 83.70% | 80.50% | 78.17% | 75.22% | 73.16% | 71.77% | 70.36% | 69.42% | 68.06% | 67.05% | 66.26% | 65.78% | 65.46% | 65.24% |
| COMBINED | 97.79% | 91.55% | 86.24% | 81.86% | 78.44% | 75.69% | 72.69% | 70.49% | 68.66% | 67.05% | 66.11% | 64.97% | 63.73% | 63.07% | 62.37% | 62.05% | 61.75% |
| CHILDREN | 97.64% | 91.17% | 84.59% | 79.50% | 75.77% | 72.53% | 69.45% | 67.03% | 64.67% | 62.79% | 61.84% | 60.95% | 59.42% | 58.90% | 57.94% | 57.62% | 57.20% |




FOR ADULTS




REMOVAL RATES ANALYSIS FOR ALL ANALYSIS CATEGORIES AND DIFFERENT PATIENTS POPULATION



REMOVAL RATES ANALYSIS CATEGORIES FOR CHILDREN



REMOVAL RATES ANALYSIS CATEGORIES FOR ADULTS AND CHILDREN



COMBINED ADULTS AND CHILDREN

| V " | Medical CRP | Device CRP | Inconclusive CRP | Tatal All Catagorica | To | otal |
|------|-------------|------------|------------------|----------------------|--------|---------|
| Year | Medical CRP | Device CRP | inconclusive CRP | Total All Categories | CI Up | CI Down |
| 1 | 0.98% | 3.14% | 0.00% | 4.09% | 4.70% | 3.48% |
| 2 | 1.32% | 11.11% | 0.08% | 12.36% | 13.37% | 11.35% |
| 3 | 1.58% | 17.53% | 0.14% | 18.95% | 20.16% | 17.75% |
| 4 | 1.74% | 22.69% | 0.17% | 24.16% | 25.48% | 22.84% |
| 5 | 1.90% | 26.67% | 0.24% | 28.24% | 29.63% | 26.85% |
| 6 | 2.04% | 29.65% | 0.24% | 31.25% | 32.68% | 29.82% |
| 7 | 2.12% | 32.76% | 0.24% | 34.34% | 35.81% | 32.87% |
| 8 | 2.39% | 34.95% | 0.24% | 36.66% | 38.15% | 35.17% |
| 9 | 2.42% | 36.79% | 0.24% | 38.47% | 39.98% | 36.97% |
| 10 | 2.55% | 38.43% | 0.24% | 40.14% | 41.66% | 38.62% |
| 11 | 2.63% | 39.44% | 0.24% | 41.18% | 42.70% | 39.65% |
| 12 | 2.80% | 40.60% | 0.33% | 42.45% | 43.98% | 40.92% |
| 13 | 2.84% | 41.83% | 0.33% | 43.67% | 45.21% | 42.13% |
| 14 | 2.98% | 42.52% | 0.37% | 44.44% | 45.98% | 42.89% |
| 15 | 3.02% | 43.26% | 0.37% | 45.18% | 46.72% | 43.63% |
| 16 | 3.07% | 43.70% | 0.43% | 45.67% | 47.22% | 44.12% |
| 17 | 3.17% | 44.20% | 0.43% | 46.20% | 47.77% | 44.63% |

CII BIONIC EAR

The CII Bionic Ear cochlear implant is the base for the advanced technology found in Advanced Bionics implants today. The platform can still take advantage of the latest innovations today. It benefited from the mechanical improvement made to the earlier C1.2 implants.

Number of registered CII implants


As of September 30, 2021 Last year of distribution^a: 2004

| STANDARD | ADULTS | CHILDREN | COMBINED |
|-----------------|--------|----------|-------------------|
| ISO 5841-2:2014 | 3000 | 2084 | 5108 ^b |
| ANSI/AAMI CI86 | 3381° | 1727 | 5108 |



b. The combined number also includes any registered users for whom we do not have date of birth information.

ISO 5841-2:2014




| Years in use | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 19 | 20 |
|--------------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|
| ADULTS | 99.77% | 99.70% | 99.60% | 99.53% | 99.50% | 99.43% | 99.39% | 99.32% | 99.25% | 99.22% | 99.12% | 99.12% | 99.08% | 99.05% | 99.01% | 98.98% | 98.94% | 98.90% | 98.82% | 98.82% |
| COMBINED | 99.61% | 99.35% | 99.01% | 98.83% | 98.67% | 98.43% | 98.33% | 98.14% | 97.94% | 97.88% | 97.77% | 97.71% | 97.65% | 97.55% | 97.52% | 97.44% | 97.40% | 97.33% | 97.28% | 97.23% |
| CHILDREN | 99.37% | 98.84% | 98.15% | 97.81% | 97.46% | 96.96% | 96.76% | 96.40% | 96.00% | 95.89% | 95.79% | 95.64% | 95.53% | 95.32% | 95.32% | 95.17% | 95.12% | 95.00% | 95.00% | 94.88% |




c. The adult number also includes users whose personal information is not available or may not be obtainable due to certain privacy laws in certain countries.




REMOVAL RATES ANALYSIS FOR ALL ANALYSIS CATEGORIES AND DIFFERENT PATIENTS POPULATION






REMOVAL RATES ANALYSIS CATEGORIES FOR CHILDREN

REMOVAL RATES ANALYSIS CATEGORIES FOR ADULTS AND CHILDREN





COMBINED ADULTS AND CHILDREN

| | COMBINED ADDETS AND CHIEDREN | | | | | | | |
|------|------------------------------|------------|----------------------|----------------------|-------|---------|--|--|
| V " | Madiaal CDD | Davies CDD | In a small raise CDD | Total All Catagorica | To | otal | | |
| Year | Medical CRP | Device CRP | Inconclusive CRP | Total All Categories | CI Up | CI Down | | |
| 1 | 0.47% | 0.55% | 0.06% | 1.08% | 1.36% | 0.79% | | |
| 2 | 0.89% | 0.81% | 0.22% | 1.90% | 2.27% | 1.52% | | |
| 3 | 1.24% | 1.22% | 0.32% | 2.76% | 3.21% | 2.31% | | |
| 4 | 1.50% | 1.42% | 0.42% | 3.31% | 3.80% | 2.82% | | |
| 5 | 1.74% | 1.66% | 0.54% | 3.90% | 4.43% | 3.37% | | |
| 6 | 1.92% | 2.03% | 0.68% | 4.57% | 5.14% | 4.00% | | |
| 7 | 2.05% | 2.25% | 0.85% | 5.06% | 5.66% | 4.46% | | |
| 8 | 2.17% | 2.45% | 1.01% | 5.53% | 6.16% | 4.91% | | |
| 9 | 2.37% | 2.66% | 1.09% | 6.01% | 6.66% | 5.35% | | |
| 10 | 2.54% | 2.84% | 1.09% | 6.34% | 7.01% | 5.67% | | |
| 11 | 2.64% | 2.94% | 1.18% | 6.62% | 7.30% | 5.93% | | |
| 12 | 2.89% | 3.00% | 1.22% | 6.95% | 7.65% | 6.25% | | |
| 13 | 3.03% | 3.09% | 1.24% | 7.19% | 7.90% | 6.48% | | |
| 14 | 3.13% | 3.23% | 1.26% | 7.44% | 8.16% | 6.72% | | |
| 15 | 3.24% | 3.29% | 1.26% | 7.60% | 8.33% | 6.87% | | |
| 16 | 3.32% | 3.35% | 1.28% | 7.76% | 8.49% | 7.02% | | |
| 17 | 3.46% | 3.39% | 1.33% | 7.98% | 8.72% | 7.23% | | |
| 18 | 3.55% | 3.46% | 1.37% | 8.16% | 8.91% | 7.41% | | |
| 19 | 3.74% | 3.54% | 1.37% | 8.42% | 9.18% | 7.65% | | |
| 20 | 3.83% | 3.54% | 1.42% | 8.55% | 9.33% | 7.77% | | |
| | | | | | | | | |

CLARION 1.2

The Clarion 1.2 (C1.2) implant offers mechanical improvements over its predecessor the C1.0 implant, which first introduced independent current-sources, a key technology differentiator for Advanced Bionics implants.

Number of registered C1.2 implants


As of September 30, 2021 Last year of distribution^a: 2004

| STANDARD | ADULTS | CHILDREN | COMBINED |
|-----------------|--------|----------|-------------------|
| ISO 5841-2:2014 | 4315 | 4149 | 8501 ^b |
| ANSI/AAMI CI86 | 4964° | 3537 | 8501 |



b. The combined number also includes any registered users for whom we do not have date of birth information.

ISO 5841-2:2014




| Years in use | | | | | 5 | 6 | | 8 | 9 | 10 | 11 | 12 | 13 |
|--------------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|
| ADULTS | 99.81% | 99.56% | 98.83% | 97.76% | 96.57% | 95.66% | 94.77% | 93.73% | 93.08% | 92.30% | 91.51% | 90.97% | 90.55% |
| COMBINED | 99.42% | 98.72% | 97.36% | 95.75% | 94.10% | 92.51% | 91.34% | 89.93% | 89.01% | 87.94% | 87.09% | 86.49% | 85.95% |
| CHILDREN | 99.00% | 97.83% | 95.80% | 93.61% | 91.46% | 89.14% | 87.66% | 85.83% | 84.63% | 83.23% | 82.30% | 81.62% | 80.95% |
| | | | | | | | | | | | | | |


| Years in use | 14 | 15 | 16 | 17 | 18 | 19 | 20 | 21 | 22 | 23 | 24 | 25 |
|--------------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|
| ADULTS | 90.13% | 89.81% | 89.48% | 89.08% | 88.77% | 88.46% | 88.22% | 88.13% | 88.01% | 87.89% | 87.79% | 87.79% |
| COMBINED | 85.54% | 84.84% | 84.30% | 83.80% | 83.34% | 82.98% | 82.69% | 82.41% | 82.15% | 82.02% | 81.74% | 81.74% |
| CHILDREN | 80.54% | 79.41% | 78.63% | 78.01% | 77.37% | 76.95% | 76.60% | 76.08% | 75.64% | 75.49% | 74.98% | 74.98% |

c. The adult number also includes users whose personal information is not available or may not be obtainable due to certain privacy laws in certain countries.

REMOVAL RATES ANALYSIS CATEGORIES FOR ADULTS


REMOVAL RATES ANALYSIS FOR ALL ANALYSIS CATEGORIES AND DIFFERENT PATIENTS POPULATION






REMOVAL RATES ANALYSIS CATEGORIES FOR CHILDREN

REMOVAL RATES ANALYSIS CATEGORIES FOR ADULTS AND CHILDREN





COMBINED ADULTS AND CHILDREN

| | | | | | To | otal |
|------|-------------|------------|------------------|----------------------|--------|---------|
| Year | Medical CRP | Device CRP | Inconclusive CRP | Total All Categories | CI Up | CI Down |
| 1 | 0.36% | 0.97% | 0.13% | 1.45% | 1.70% | 1.19% |
| 2 | 0.50% | 1.80% | 0.24% | 2.52% | 2.86% | 2.19% |
| 3 | 0.68% | 3.26% | 0.41% | 4.31% | 4.74% | 3.88% |
| 4 | 0.88% | 4.98% | 0.58% | 6.37% | 6.89% | 5.85% |
| 5 | 1.07% | 6.67% | 0.84% | 8.45% | 9.04% | 7.85% |
| 6 | 1.37% | 8.35% | 1.01% | 10.51% | 11.16% | 9.86% |
| 7 | 1.57% | 9.65% | 1.17% | 12.10% | 12.80% | 11.41% |
| 8 | 1.80% | 11.24% | 1.38% | 14.04% | 14.78% | 13.30% |
| 9 | 2.01% | 12.22% | 1.66% | 15.41% | 16.18% | 14.64% |
| 10 | 2.25% | 13.46% | 1.99% | 17.09% | 17.90% | 16.29% |
| 11 | 2.46% | 14.36% | 2.21% | 18.31% | 19.14% | 17.49% |
| 12 | 2.72% | 14.94% | 2.44% | 19.27% | 20.11% | 18.43% |
| 13 | 2.97% | 15.49% | 2.57% | 20.11% | 20.96% | 19.25% |
| 14 | 3.22% | 15.97% | 2.67% | 20.85% | 21.72% | 19.98% |
| 15 | 3.59% | 16.70% | 2.80% | 21.94% | 22.83% | 21.06% |
| 16 | 4.08% | 17.28% | 2.97% | 23.01% | 23.91% | 22.11% |
| 17 | 4.57% | 17.83% | 3.18% | 24.08% | 25.00% | 23.17% |
| 18 | 5.46% | 18.29% | 3.31% | 25.30% | 26.23% | 24.37% |
| 19 | 6.23% | 18.65% | 3.44% | 26.34% | 27.28% | 25.40% |
| 20 | 7.10% | 18.93% | 3.57% | 27.37% | 28.33% | 26.41% |
| 21 | 7.74% | 19.18% | 3.70% | 28.20% | 29.17% | 27.23% |
| 22 | 8.33% | 19.47% | 3.83% | 29.01% | 30.00% | 28.02% |
| 23 | 9.13% | 19.60% | 3.87% | 29.77% | 30.79% | 28.75% |
| 24 | 9.81% | 19.88% | 3.93% | 30.58% | 31.66% | 29.50% |
| 25 | 10.07% | 19.88% | 3.93% | 30.78% | 31.89% | 29.67% |
| | | | | | | |

CLARION 1.0

The Clarion 1.0 (C1.0) implant was Advanced Bionics first device, the start of a technology-forward lineage that continues today. As the number of children implanted with the C1.0 is below the level required for statistical analysis, the data is included with the adult data.

Number of registered C1.0 implants


As of September 30, 2021 Last year of distribution^a: 2004

| STANDARD | ADULTS | CHILDREN | COMBINED |
|-----------------|--------|----------|------------------|
| ISO 5841-2:2014 | 316 | 49 | 367 ^b |
| ANSI/AAMI CI86 | - | - | - |



- a. Dates provided are those for major markets covered by FDA and TUV regulation. Some implants may be pending approval in a subset of additional regions.
- b. The combined number also includes any registered users for whom we do not have date of birth information.

ISO 5841-2:2014



| Years in use | | | | | 5 | 6 | | 8 | 9 | 10 | 11 | 12 | 13 |
|--------------|--------------|--------------|--------------|--------------|--------------|--------------|--------------|--------------|--------------|--------------|--------------|--------------|--------------|
| ADULTS | 97.78% | 97.47% | 96.19% | 95.56% | 94.28% | 93.32% | 93.32% | 92.68% | 91.72% | 91.39% | 90.42% | 90.42% | 90.42% |
| COMBINED | 98.09% | 96.73% | 95.63% | 95.08% | 93.99% | 92.89% | 92.89% | 92.34% | 91.50% | 91.23% | 90.39% | 90.11% | 89.55% |
| | | | | | | | | | | | | | |
| Vacro in uso | | | | | | | | | | | | | |
| Years in use | 14 | 15 | 16 | 17 | 18 | 19 | 20 | 21 | 22 | 23 | 24 | 25 | 26 |
| ADULTS | 14 89.77% | 15 89.11% | 16 88.45% | 17 88.12% | 18 88.12% | 19 88.12% | 20 88.12% | 21 87.78% | 22 87.44% | 23 87.11% | 24 86.42% | 25 85.73% | 26 85.37% |

The ANSI/AAMI CI86 Standard does not require reporting for devices older than 20 years after the last implantation of that device type. Please refer to the ISO data for information.

SOUND PROCESSOR STIMULATORS

For each currently-available sound processor, there will be a simple measure of reliability based on the average global yearly return rate and graphical data in compliance with ANSI/AAMI CI86 Standard that shows the monthly failure rate.

Where possible this monthly data is further categorized into failure mechanisms, if known, to include mechanical, electronic, moisture damage, and other. In specification processors, commonly referred to as no-fault-found, are also included. Where available, the number of registered users is shown, categorized into adult, children, and combined.




NAÍDA CI M AND SKY CI M

The Naída™ CI M sound processor for adults and Sky CI™ M sound processor for children are the newest Advanced Bionics products integrated with the latest advancements from Phonak, the Marvel platform. With built-in connectivity solutions and the ability to automatically sense and adapt to every situation, the Naída CI M and Sky CI M processors are designed to give you the best hearing experience.

Reliability of the Naída CI M and Sky CI M sound processors are combined at this time due to the limited number of devices in use. As field data becomes available globally, we will present the reliability metrics as separate products in future reports.

RELIABILITY: 99.09%a



FAILED COMPONENT RETURN RATE^b

| Cause | Apr 2021 | May 2021 | Jun 2021 | Jul 2021 | Aug 2021 | Sep 2021 |
|------------|----------|----------|----------|----------|----------|----------|
| Mechanical | 0.57% | 0.41% | 0.25% | 0.25% | 0.17% | 0.55% |
| Moisture | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Electrical | 0.00% | 0.41% | 0.31% | 0.32% | 0.34% | 0.23% |
| Other | 0.00% | 0.00% | 0.06% | 0.19% | 0.25% | 0.00% |

- a. Reliability is 1 minus the return rate. The return rate is the average global monthly return rate April 2021 to September 2021.
- b. The number per month represent the unit that complete failure analysis in that month.




NAÍDA CI Q90

The NaídaTM CI Q90 sound processor features state-of-the-art technologies exclusively available from Advanced Bionics and Phonak for the best possible hearing experience.



RELIABILITY: 99.64%a



FAILED COMPONENT RETURN RATED


| Cause | Sep 2020 | Oct 2020 | Nov 2020 | Dec 2020 | Jan 2021 | Feb 2021 | Mar 2021 | Apr 2021 | May 2021 | Jun 2021 | Jul 2021 | Aug 2021 | Sep 2021 |
|------------|----------|----------|----------|----------|----------|----------|----------|----------|----------|----------|----------|----------|----------|
| Mechanical | 0.21% | 0.27% | 0.17% | 0.14% | 0.19% | 0.16% | 0.15% | 0.19% | 0.17% | 0.29% | 0.11% | 0.27% | 0.14% |
| Moisture | 0.10% | 0.05% | 0.03% | 0.09% | 0.07% | 0.03% | 0.07% | 0.05% | 0.02% | 0.00% | 0.00% | 0.00% | 0.11% |
| Electrical | 0.18% | 0.12% | 0.11% | 0.10% | 0.09% | 0.14% | 0.14% | 0.10% | 0.08% | 0.10% | 0.21% | 0.12% | 0.08% |
| Other | 0.01% | 0.02% | 0.03% | 0.01% | 0.02% | 0.01% | 0.01% | 0.00% | 0.00% | 0.06% | 0.00% | 0.03% | 0.00% |

CHORUS

The ChorusTM sound processor is compatible with C1.0 and C1.2 cochlear implants, and offers integrated RogerTM technology for connectivity and performance.

Data set too limited for detailed analysis.

RELIABILITY: 99.73%^a




NEPTUNE

The Neptune[™] sound processor is the first and only swimmable sound processor.







FAILED COMPONENT RETURN RATE^b

| Cause | Sep 2020 | Oct 2020 | Nov 2020 | Dec 2020 | Jan 2021 | Feb 2021 | Mar 2021 | Apr 2021 | May 2021 | Jun 2021 | Jul 2021 | Aug 2021 | Sep 2021 |
|------------|----------|----------|----------|----------|----------|----------|----------|----------|----------|----------|----------|----------|----------|
| Mechanical | 0.11% | 0.03% | 0.01% | 0.03% | 0.01% | 0.00% | 0.00% | 0.04% | 0.00% | 0.05% | 0.00% | 0.09% | 0.03% |
| Moisture | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.01% | 0.00% | 0.04% | 0.00% |
| Electrical | 0.22% | 0.12% | 0.09% | 0.11% | 0.12% | 0.05% | 0.11% | 0.15% | 0.20% | 0.28% | 0.32% | 0.09% | 0.07% |
| Other | 0.01% | 0.01% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.01% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |

a. Reliability is 1 minus the return rate. The return rate is the average global monthly return rate over a 12-month period from September 2020 to September 2021.

b. The number per month represent the unit that complete failure analysis in that month.

HIRES ULTRA 3D v2

| | Year | Medical CRP | Device CRP | Inconclusive CRP | Total All Categories | To | otal |
|-------------|------|-------------|------------|------------------|----------------------|-------|---------|
| | ieai | Medical Chr | Device Chr | Inconclusive Chr | 9 | CI Up | CI Down |
| ADULTS | 1 | 0.66% | 0.00% | 0.00% | 0.66% | 0.92% | 0.40% |
| ADULIS | 1.5 | 0.66% | 0.00% | 0.00% | 0.66% | 0.92% | 0.40% |
| CIIII DDENI | 1 | 0.37% | 0.15% | 0.00% | 0.51% | 0.94% | 0.08% |
| CHILDREN | 1.5ª | NA | NA | NA | NA | NA | NA |

a. Sample size for children at 1.5 years is not large enough for reporting

HIRES ULTRA V2

| | Year Medical CR | Madical CBB | Device CRP | Inconclusive CRP | Total All Categories | To | otal |
|----------|-----------------|---------------|------------|------------------|----------------------|-------|---------|
| | | ivieuicai Chr | Device Chr | Inconclusive Chr | Total All Categories | CI Up | CI Down |
| ADULTS | 1 ^a | 0.37% | 0.00% | 0.00% | 0.37% | 0.88% | 0.00% |
| CHILDREN | 1 ^b | 0.15% | 0.00% | 0.00% | 0.15% | 0.45% | 0.00% |

b. Sufficient data to report adults at 11 months

HIRES ULTRA 3D V1

| | Year | Medical CRP | Device CRP | Inconclusive CRP | Total All Categories | To | otal |
|----------|------|-------------|------------|------------------|----------------------|-------|---------|
| | rear | Wedical Chr | Device Chr | Inconclusive Chr | <u> </u> | CI Up | CI Down |
| ADULTS | 1 | 0.94% | 0.16% | 0.02% | 1.12% | 1.41% | 0.83% |
| ADULIS | 2 | 1.60% | 1.66% | 0.08% | 3.32% | 3.83% | 2.81% |
| CHILDREN | 1 | 1.04% | 0.45% | 0.00% | 1.48% | 2.13% | 0.84% |
| CHILDREN | 2 | 1.67% | 5.89% | 0.00% | 7.47% | 8.94% | 6.00% |

HIRES ULTRA V1

| | Year | Medical CRP | Device CRP | Inconclusive CRP | Total All Categories | Total | | |
|----------|------|-------------|------------|------------------|----------------------|--------|---------|--|
| | Teal | Medical Chr | Device Onr | Inconclusive Onf | Total All Categories | CI Up | CI Down | |
| | 1 | 0.75% | 0.02% | 0.02% | 0.80% | 0.99% | 0.61% | |
| ADULTS | 2 | 1.24% | 0.37% | 0.04% | 1.64% | 1.92% | 1.37% | |
| ADULIS | 3 | 1.60% | 2.83% | 0.06% | 4.45% | 4.93% | 3.98% | |
| | 4 | 1.91% | 8.06% | 0.11% | 9.92% | 10.76% | 9.07% | |
| | 1 | 0.56% | 0.11% | 0.00% | 0.66% | 0.92% | 0.40% | |
| CHILDREN | 2 | 0.78% | 1.07% | 0.03% | 1.86% | 2.30% | 1.42% | |
| CHILDREN | 3 | 1.03% | 5.80% | 0.11% | 6.87% | 7.83% | 5.91% | |
| | 4 | 1.84% | 16.66% | 0.11% | 18.29% | 20.24% | 16.33% | |

c. Sufficient data to report children at 10 months

HIRES 90K ADVANTAGE

| | Year | Medical CRP | Device CRP | Inconclusive CRP | Total All Categories | To | otal |
|----------|------|-------------|------------|------------------|----------------------|-------|---------|
| | Teal | Medical Chr | Device Chr | Inconclusive Chr | Total All Categories | CI Up | CI Down |
| | 1 | 0.68% | 0.07% | 0.02% | 0.76% | 0.89% | 0.64% |
| | 2 | 1.16% | 0.09% | 0.03% | 1.27% | 1.43% | 1.12% |
| | 3 | 1.42% | 0.14% | 0.04% | 1.60% | 1.78% | 1.42% |
| ADULTS | 4 | 1.71% | 0.17% | 0.04% | 1.92% | 2.12% | 1.73% |
| ADULI 5 | 5 | 1.89% | 0.20% | 0.04% | 2.13% | 2.34% | 1.92% |
| | 6 | 2.06% | 0.23% | 0.05% | 2.34% | 2.56% | 2.11% |
| | 7 | 2.21% | 0.24% | 0.07% | 2.51% | 2.76% | 2.27% |
| | 8 | 2.36% | 0.27% | 0.07% | 2.69% | 2.97% | 2.41% |
| | 1 | 0.77% | 0.21% | 0.03% | 1.01% | 1.15% | 0.86% |
| | 2 | 1.10% | 0.38% | 0.05% | 1.53% | 1.71% | 1.35% |
| | 3 | 1.39% | 0.60% | 0.05% | 2.03% | 2.24% | 1.82% |
| CHILDREN | 4 | 1.59% | 0.76% | 0.10% | 2.44% | 2.68% | 2.20% |
| CHILDREN | 5 | 1.74% | 0.88% | 0.17% | 2.76% | 3.02% | 2.50% |
| | 6 | 1.88% | 1.04% | 0.18% | 3.08% | 3.36% | 2.79% |
| | 7 | 2.03% | 1.25% | 0.20% | 3.45% | 3.78% | 3.11% |
| | 8 | 2.12% | 1.38% | 0.20% | 3.67% | 4.05% | 3.28% |

HIRES 90K vendor A post-mod

| | Voor | Madical CDD | Davisa CDD | Incomplyaina CDD | Total All Catagorias | To | otal |
|-----------|------|-------------|------------|------------------|----------------------|-------|---------|
| | Year | Medical CRP | Device CRP | Inconclusive CRP | Total All Categories | CI Up | CI Down |
| | 1 | 0.80% | 0.06% | 0.02% | 0.88% | 0.97% | 0.78% |
| | 2 | 1.32% | 0.11% | 0.04% | 1.46% | 1.58% | 1.34% |
| | 3 | 1.63% | 0.16% | 0.06% | 1.85% | 1.98% | 1.71% |
| | 4 | 1.92% | 0.23% | 0.08% | 2.22% | 2.37% | 2.08% |
| | 5 | 2.13% | 0.27% | 0.09% | 2.48% | 2.64% | 2.33% |
| | 6 | 2.29% | 0.34% | 0.11% | 2.73% | 2.89% | 2.56% |
| | 7 | 2.43% | 0.36% | 0.13% | 2.91% | 3.08% | 2.73% |
| ADULTS | 8 | 2.59% | 0.44% | 0.13% | 3.14% | 3.33% | 2.96% |
| ADULIS | 9 | 2.67% | 0.47% | 0.14% | 3.26% | 3.45% | 3.07% |
| | 10 | 2.79% | 0.55% | 0.15% | 3.47% | 3.67% | 3.26% |
| | 11 | 2.85% | 0.60% | 0.15% | 3.57% | 3.78% | 3.36% |
| | 12 | 2.98% | 0.61% | 0.15% | 3.71% | 3.93% | 3.49% |
| | 13 | 3.12% | 0.63% | 0.16% | 3.88% | 4.12% | 3.65% |
| | 14 | 3.22% | 0.63% | 0.18% | 4.00% | 4.24% | 3.75% |
| | 15 | 3.33% | 0.66% | 0.18% | 4.14% | 4.42% | 3.86% |
| | 16 | 3.33% | 0.74% | 0.18% | 4.22% | 4.53% | 3.90% |
| | 1 | 0.82% | 0.21% | 0.03% | 1.05% | 1.15% | 0.95% |
| | 2 | 1.14% | 0.47% | 0.04% | 1.65% | 1.77% | 1.52% |
| | 3 | 1.40% | 0.74% | 0.06% | 2.19% | 2.34% | 2.05% |
| | 4 | 1.60% | 1.01% | 0.09% | 2.68% | 2.84% | 2.51% |
| | 5 | 1.77% | 1.22% | 0.13% | 3.09% | 3.27% | 2.91% |
| | 6 | 1.90% | 1.40% | 0.14% | 3.41% | 3.60% | 3.22% |
| | 7 | 2.02% | 1.52% | 0.16% | 3.67% | 3.87% | 3.47% |
| CHILDREN | 8 | 2.11% | 1.66% | 0.18% | 3.91% | 4.12% | 3.69% |
| CHILDHLIN | 9 | 2.24% | 1.79% | 0.19% | 4.18% | 4.41% | 3.95% |
| | 10 | 2.47% | 1.95% | 0.23% | 4.59% | 4.85% | 4.33% |
| | 11 | 2.59% | 1.98% | 0.26% | 4.76% | 5.04% | 4.49% |
| | 12 | 2.76% | 2.07% | 0.30% | 5.06% | 5.36% | 4.76% |
| | 13 | 2.90% | 2.11% | 0.30% | 5.23% | 5.55% | 4.92% |
| | 14 | 3.04% | 2.14% | 0.32% | 5.41% | 5.76% | 5.07% |
| | 15 | 3.09% | 2.24% | 0.38% | 5.61% | 6.00% | 5.22% |
| | 16 | N/A | N/A | N/A | N/A | N/A | N/A |

HIRES 90K vendor A all

| | Year | Medical CRP | Device CRP | Inconclusive CRP | Total All Catagorias | To | otal |
|-----------|------|-------------|------------|------------------|----------------------|-------|---------|
| | rear | Medical CRP | Device CRP | inconclusive CRP | Total All Categories | CI Up | CI Down |
| | 1 | 0.79% | 0.08% | 0.01% | 0.88% | 0.97% | 0.79% |
| | 2 | 1.30% | 0.14% | 0.05% | 1.49% | 1.60% | 1.37% |
| | 3 | 1.61% | 0.20% | 0.08% | 1.89% | 2.02% | 1.75% |
| | 4 | 1.90% | 0.30% | 0.10% | 2.29% | 2.44% | 2.15% |
| | 5 | 2.11% | 0.36% | 0.11% | 2.57% | 2.72% | 2.41% |
| | 6 | 2.27% | 0.44% | 0.14% | 2.84% | 3.00% | 2.67% |
| | 7 | 2.42% | 0.48% | 0.15% | 3.03% | 3.21% | 2.86% |
| | 8 | 2.57% | 0.59% | 0.16% | 3.29% | 3.48% | 3.11% |
| ADULTS | 9 | 2.65% | 0.68% | 0.16% | 3.46% | 3.65% | 3.27% |
| ADULIS | 10 | 2.77% | 0.78% | 0.18% | 3.70% | 3.90% | 3.49% |
| | 11 | 2.83% | 0.86% | 0.18% | 3.84% | 4.06% | 3.63% |
| | 12 | 2.98% | 0.92% | 0.18% | 4.05% | 4.27% | 3.82% |
| | 13 | 3.11% | 0.98% | 0.20% | 4.24% | 4.48% | 4.01% |
| | 14 | 3.25% | 1.07% | 0.21% | 4.48% | 4.74% | 4.22% |
| | 15 | 3.34% | 1.15% | 0.21% | 4.66% | 4.94% | 4.37% |
| | 16 | 3.38% | 1.26% | 0.21% | 4.79% | 5.11% | 4.48% |
| | 17 | 3.44% | 1.32% | 0.27% | 4.97% | 5.34% | 4.60% |
| | 18 | N/A | N/A | N/A | N/A | N/A | N/A |
| | 1 | 0.83% | 0.22% | 0.03% | 1.08% | 1.18% | 0.97% |
| | 2 | 1.15% | 0.49% | 0.04% | 1.68% | 1.80% | 1.55% |
| | 3 | 1.42% | 0.78% | 0.06% | 2.25% | 2.39% | 2.10% |
| | 4 | 1.63% | 1.06% | 0.09% | 2.76% | 2.92% | 2.59% |
| | 5 | 1.79% | 1.29% | 0.13% | 3.19% | 3.36% | 3.01% |
| | 6 | 1.92% | 1.49% | 0.15% | 3.52% | 3.72% | 3.33% |
| | 7 | 2.06% | 1.63% | 0.17% | 3.83% | 4.03% | 3.63% |
| | 8 | 2.17% | 1.81% | 0.19% | 4.13% | 4.34% | 3.91% |
| CHILDREN | 9 | 2.29% | 1.96% | 0.21% | 4.40% | 4.63% | 4.17% |
| CHILDHLIN | 10 | 2.51% | 2.13% | 0.25% | 4.83% | 5.09% | 4.57% |
| | 11 | 2.65% | 2.21% | 0.29% | 5.07% | 5.35% | 4.79% |
| | 12 | 2.81% | 2.38% | 0.32% | 5.43% | 5.73% | 5.13% |
| | 13 | 2.93% | 2.46% | 0.32% | 5.62% | 5.94% | 5.30% |
| | 14 | 3.04% | 2.64% | 0.34% | 5.92% | 6.27% | 5.56% |
| | 15 | 3.11% | 2.85% | 0.38% | 6.23% | 6.63% | 5.82% |
| | 16 | 3.24% | 3.10% | 0.45% | 6.65% | 7.17% | 6.14% |
| | 17 | 3.24% | 3.45% | 0.45% | 6.99% | 7.63% | 6.35% |
| | 18 | N/A | N/A | N/A | N/A | N/A | N/A |

HIRES 90K vendor A pre-mod

| | Year | Medical CRP | Device CRP | Inconclusive CRP | Total All Categories | To | otal |
|---------|------|-------------|------------|------------------|----------------------|--------|---------|
| | rear | Medical Chr | Device Chr | Inconclusive Chr | Total All Categories | CI Up | CI Down |
| | 1 | 0.68% | 0.40% | 0.00% | 1.08% | 1.56% | 0.60% |
| | 2 | 0.97% | 0.80% | 0.23% | 1.99% | 2.64% | 1.34% |
| | 3 | 1.26% | 1.03% | 0.46% | 2.73% | 3.49% | 1.97% |
| | 4 | 1.55% | 1.78% | 0.52% | 3.81% | 4.70% | 2.91% |
| | 5 | 1.66% | 2.19% | 0.58% | 4.38% | 5.33% | 3.42% |
| | 6 | 1.90% | 2.60% | 0.64% | 5.06% | 6.09% | 4.04% |
| | 7 | 2.08% | 2.83% | 0.70% | 5.52% | 6.58% | 4.45% |
| | 8 | 2.13% | 3.36% | 0.70% | 6.09% | 7.20% | 4.97% |
| ADULTS | 9 | 2.19% | 4.01% | 0.70% | 6.77% | 7.95% | 5.60% |
| ADULI S | 10 | 2.31% | 4.36% | 0.76% | 7.29% | 8.50% | 6.07% |
| | 11 | 2.44% | 4.72% | 0.76% | 7.74% | 8.99% | 6.49% |
| | 12 | 2.68% | 5.13% | 0.76% | 8.37% | 9.67% | 7.08% |
| | 13 | 2.74% | 5.37% | 0.82% | 8.72% | 10.04% | 7.40% |
| | 14 | 3.04% | 5.79% | 0.82% | 9.41% | 10.77% | 8.04% |
| | 15 | 3.11% | 5.96% | 0.82% | 9.64% | 11.02% | 8.25% |
| | 16 | 3.17% | 6.08% | 0.82% | 9.81% | 11.20% | 8.42% |
| | 17 | 3.24% | 6.15% | 0.89% | 10.00% | 11.41% | 8.60% |
| | 18 | N/A | N/A | N/A | N/A | N/A | N/A |

| | Vaar | Madiaal CDD | Daviss CDD | Jacobski in CDD | Tatal All Catagories | Total | |
|----------|------|-------------|------------|------------------|----------------------|--------|---------|
| | Year | Medical CRP | Device CRP | Inconclusive CRP | Total All Categories | CI Up | CI Down |
| | 1 | 1.26% | 0.74% | 0.00% | 1.98% | 2.87% | 1.10% |
| | 2 | 1.57% | 1.27% | 0.11% | 2.93% | 3.99% | 1.86% |
| | 3 | 2.11% | 2.02% | 0.22% | 4.29% | 5.57% | 3.01% |
| | 4 | 2.65% | 2.88% | 0.22% | 5.66% | 7.12% | 4.19% |
| | 5 | 2.76% | 3.64% | 0.33% | 6.60% | 8.18% | 5.03% |
| | 6 | 2.76% | 4.40% | 0.44% | 7.44% | 9.11% | 5.78% |
| CHILDREN | 7 | 3.31% | 5.16% | 0.67% | 8.91% | 10.72% | 7.10% |
| | 8 | 3.87% | 6.15% | 0.67% | 10.38% | 12.32% | 8.45% |
| | 9 | 3.87% | 6.48% | 0.67% | 10.70% | 12.66% | 8.74% |
| | 10 | 3.99% | 6.92% | 0.79% | 11.33% | 13.34% | 9.32% |
| | 11 | 4.33% | 7.36% | 0.90% | 12.17% | 14.25% | 10.10% |
| | 12 | 4.33% | 8.25% | 0.90% | 13.01% | 15.15% | 10.88% |
| | 13 | 4.33% | 8.58% | 0.90% | 13.33% | 15.49% | 11.17% |
| | 14 | 4.33% | 9.36% | 0.90% | 14.07% | 16.28% | 11.86% |
| | 15 | 4.45% | 9.81% | 0.90% | 14.60% | 16.84% | 12.36% |
| | 16 | 4.45% | 10.03% | 0.90% | 14.81% | 17.07% | 12.55% |
| | 17 | 4.45% | 10.43% | 0.90% | 15.18% | 17.47% | 12.90% |
| | 18 | N/A | N/A | N/A | N/A | N/A | N/A |

HIRES 90K vendor B

| | V | Madian ODD | D ODD | la constant a ODD | Tatal All Oatawaiia | Total | |
|----------|------|-------------|------------|-------------------|----------------------|--------|---------|
| | Year | Medical CRP | Device CRP | Inconclusive CRP | Total All Categories | CI Up | CI Down |
| | 1 | 1.03% | 3.03% | 0.00% | 4.03% | 4.79% | 3.27% |
| | 2 | 1.33% | 10.84% | 0.09% | 12.10% | 13.37% | 10.84% |
| | 3 | 1.65% | 16.16% | 0.18% | 17.69% | 19.17% | 16.21% |
| | 4 | 1.84% | 20.68% | 0.23% | 22.31% | 23.93% | 20.70% |
| | 5 | 1.94% | 24.29% | 0.28% | 25.97% | 27.67% | 24.26% |
| | 6 | 2.05% | 26.73% | 0.28% | 28.44% | 30.19% | 26.68% |
| | 7 | 2.16% | 29.76% | 0.28% | 31.47% | 33.28% | 29.66% |
| | 8 | 2.45% | 31.65% | 0.28% | 33.51% | 35.35% | 31.67% |
| ADULTS | 9 | 2.45% | 33.21% | 0.28% | 35.03% | 36.89% | 33.17% |
| | 10 | 2.63% | 34.70% | 0.28% | 36.60% | 38.48% | 34.72% |
| | 11 | 2.63% | 35.66% | 0.28% | 37.53% | 39.42% | 35.64% |
| | 12 | 2.70% | 36.99% | 0.28% | 38.86% | 40.76% | 36.96% |
| | 13 | 2.76% | 38.04% | 0.28% | 39.92% | 41.83% | 38.00% |
| | 14 | 2.90% | 38.83% | 0.28% | 40.77% | 42.69% | 38.85% |
| | 15 | 2.96% | 39.46% | 0.28% | 41.42% | 43.35% | 39.50% |
| | 16 | 3.04% | 39.97% | 0.28% | 41.96% | 43.89% | 40.03% |
| | 17 | 3.04% | 40.40% | 0.28% | 42.37% | 44.33% | 40.42% |
| | 1 | 0.88% | 3.34% | 0.00% | 4.19% | 5.21% | 3.18% |
| | 2 | 1.31% | 11.58% | 0.07% | 12.80% | 14.49% | 11.11% |
| | 3 | 1.47% | 19.87% | 0.07% | 21.11% | 23.18% | 19.04% |
| | 4 | 1.56% | 26.10% | 0.07% | 27.31% | 29.57% | 25.05% |
| | 5 | 1.84% | 30.72% | 0.17% | 32.11% | 34.49% | 29.74% |
| | 6 | 2.04% | 34.59% | 0.17% | 36.04% | 38.48% | 33.60% |
| | 7 | 2.04% | 37.85% | 0.17% | 39.23% | 41.71% | 36.75% |
| | 8 | 2.27% | 40.56% | 0.17% | 42.01% | 44.52% | 39.50% |
| CHILDREN | 9 | 2.39% | 42.86% | 0.17% | 44.32% | 46.85% | 41.80% |
| | 10 | 2.39% | 44.75% | 0.17% | 46.16% | 48.70% | 43.62% |
| | 11 | 2.63% | 45.87% | 0.17% | 47.39% | 49.93% | 44.85% |
| | 12 | 3.02% | 46.71% | 0.43% | 48.55% | 51.09% | 46.00% |
| | 13 | 3.02% | 48.27% | 0.43% | 50.05% | 52.60% | 47.50% |
| | 14 | 3.15% | 48.77% | 0.57% | 50.66% | 53.21% | 48.12% |
| | 15 | 3.15% | 49.69% | 0.57% | 51.56% | 54.10% | 49.01% |
| | 16 | 3.15% | 50.04% | 0.74% | 51.97% | 54.52% | 49.42% |
| | 17 | N/A | N/A | N/A | N/A | N/A | N/A |

CII BIONIC EAR

| | | | D : 033 | | - | Total | |
|-----------|------|-------------|------------|------------------|----------------------|--------|---------|
| | Year | Medical CRP | Device CRP | Inconclusive CRP | Total All Categories | CI Up | CI Down |
| | 1 | 0.47% | 0.39% | 0.03% | 0.89% | 1.20% | 0.57% |
| | 2 | 0.83% | 0.42% | 0.18% | 1.42% | 1.82% | 1.02% |
| | 3 | 1.07% | 0.59% | 0.30% | 1.95% | 2.42% | 1.49% |
| | 4 | 1.37% | 0.66% | 0.39% | 2.40% | 2.91% | 1.88% |
| | 5 | 1.55% | 0.75% | 0.42% | 2.69% | 3.24% | 2.15% |
| | 6 | 1.67% | 0.90% | 0.48% | 3.02% | 3.60% | 2.44% |
| | 7 | 1.79% | 0.96% | 0.66% | 3.38% | 3.99% | 2.77% |
| | 8 | 1.91% | 1.05% | 0.76% | 3.67% | 4.31% | 3.04% |
| | 9 | 2.12% | 1.14% | 0.82% | 4.03% | 4.69% | 3.37% |
| ADULTS | 10 | 2.27% | 1.20% | 0.82% | 4.24% | 4.92% | 3.56% |
| ADULI 5 | 11 | 2.36% | 1.29% | 0.85% | 4.45% | 5.14% | 3.75% |
| | 12 | 2.58% | 1.29% | 0.88% | 4.68% | 5.40% | 3.97% |
| | 13 | 2.64% | 1.36% | 0.88% | 4.80% | 5.52% | 4.08% |
| | 14 | 2.70% | 1.45% | 0.88% | 4.95% | 5.68% | 4.22% |
| | 15 | 2.82% | 1.51% | 0.88% | 5.13% | 5.88% | 4.39% |
| | 16 | 2.88% | 1.57% | 0.88% | 5.25% | 6.00% | 4.50% |
| | 17 | 2.94% | 1.63% | 0.88% | 5.37% | 6.13% | 4.61% |
| | 18 | 3.04% | 1.67% | 0.91% | 5.52% | 6.29% | 4.75% |
| | 19 | 3.11% | 1.74% | 0.91% | 5.67% | 6.45% | 4.89% |
| | 20 | 3.18% | 1.74% | 0.91% | 5.74% | 6.53% | 4.94% |
| | 1 | 0.47% | 0.87% | 0.12% | 1.45% | 2.01% | 0.88% |
| | 2 | 0.99% | 1.57% | 0.29% | 2.84% | 3.62% | 2.06% |
| | 3 | 1.59% | 2.46% | 0.35% | 4.35% | 5.31% | 3.39% |
| | 4 | 1.77% | 2.93% | 0.48% | 5.10% | 6.14% | 4.07% |
| | 5 | 2.13% | 3.47% | 0.78% | 6.27% | 7.41% | 5.12% |
| | 6 | 2.44% | 4.25% | 1.09% | 7.61% | 8.86% | 6.35% |
| | 7 | 2.56% | 4.80% | 1.22% | 8.36% | 9.67% | 7.06% |
| | 8 | 2.69% | 5.22% | 1.53% | 9.18% | 10.54% | 7.81% |
| | 9 | 2.87% | 5.65% | 1.66% | 9.88% | 11.29% | 8.47% |
| CHILDREN | 10 | 3.06% | 6.08% | 1.66% | 10.46% | 11.91% | 9.02% |
| CHILDHLIN | 11 | 3.19% | 6.20% | 1.85% | 10.87% | 12.34% | 9.40% |
| | 12 | 3.51% | 6.38% | 1.92% | 11.40% | 12.90% | 9.89% |
| | 13 | 3.82% | 6.51% | 1.98% | 11.86% | 13.39% | 10.33% |
| | 14 | 4.02% | 6.75% | 2.05% | 12.33% | 13.88% | 10.78% |
| | 15 | 4.08% | 6.82% | 2.05% | 12.45% | 14.01% | 10.89% |
| | 16 | 4.21% | 6.88% | 2.11% | 12.68% | 14.25% | 11.11% |
| | 17 | 4.53% | 6.88% | 2.24% | 13.09% | 14.69% | 11.50% |
| | 18 | 4.60% | 7.01% | 2.31% | 13.34% | 14.95% | 11.73% |
| | 19 | 5.04% | 7.10% | 2.31% | 13.83% | 15.47% | 12.18% |
| | 20 | 5.20% | 7.10% | 2.47% | 14.11% | 15.79% | 12.42% |

CLARION 1.2

| | V | Madia - LODB | Davis - ODB | la con el cei de ODB | Tatal All Catanasia | Total | |
|----------|------|--------------|-------------|----------------------|----------------------|--------|----------------|
| | Year | Medical CRP | Device CRP | Inconclusive CRP | Total All Categories | CI Up | CI Down |
| | 1 | 0.40% | 0.30% | 0.14% | 0.85% | 1.10% | 0.59% |
| | 2 | 0.55% | 0.65% | 0.26% | 1.45% | 1.79% | 1.12% |
| | 3 | 0.75% | 1.38% | 0.41% | 2.53% | 2.96% | 2.09% |
| | 4 | 0.94% | 2.51% | 0.60% | 4.00% | 4.55% | 3.46% |
| | 5 | 1.15% | 3.79% | 0.74% | 5.61% | 6.25% | 4.96% |
| | 6 | 1.41% | 4.83% | 0.83% | 6.94% | 7.65% | 6.23% |
| | 7 | 1.51% | 5.72% | 0.92% | 8.00% | 8.76% | 7.24% |
| | 8 | 1.71% | 6.91% | 1.05% | 9.46% | 10.28% | 8.64% |
| | 9 | 1.84% | 7.62% | 1.20% | 10.42% | 11.27% | 9.56% |
| | 10 | 2.09% | 8.57% | 1.41% | 11.74% | 12.64% | 10.84% |
| | 11 | 2.27% | 9.31% | 1.50% | 12.70% | 13.63% | 11.77% |
| | 12 | 2.55% | 9.82% | 1.71% | 13.62% | 14.57% | 12.66% |
| ADULTS | 13 | 2.76% | 10.31% | 1.75% | 14.31% | 15.29% | 13.33% |
| | 14 | 2.94% | 10.69% | 1.85% | 14.92% | 15.92% | 13.93% |
| | 15 | 3.22% | 11.12% | 1.92% | 15.64% | 16.65% | 14.62% |
| | 16 | 3.58% | 11.51% | 1.99% | 16.38% | 17.41% | 15.34% |
| | 17 | 4.03% | 11.93% | 2.06% | 17.22% | 18.27% | 16.16% |
| | 18 | 4.79% | 12.28% | 2.09% | 18.23% | 19.31% | 17.15% |
| | 19 | 5.28% | 12.57% | 2.19% | 19.00% | 20.10% | 17.91% |
| | 20 | 5.89% | 12.78% | 2.29% | 19.80% | 20.92% | 18.68% |
| | 21 | 6.42% | 12.94% | 2.38% | 20.46% | 21.60% | 19.33% |
| | 22 | 6.74% | 13.11% | 2.46% | 20.95% | 22.10% | 19.80% |
| | 23 | 7.57% | 13.21% | 2.46% | 21.75% | 22.95% | 20.55% |
| | 24 | 8.04% | 13.39% | 2.46% | 22.31% | 23.57% | 21.05% |
| | 25 | N/A | N/A | N/A | N/A | N/A | N/A |
| | 1 | 0.29% | 1.90% | 0.11% | 2.30% | 2.79% | 1.80% |
| | 2 | 0.43% | 3.42% | 0.20% | 4.03% | 4.68% | 3.38% |
| | 3 | 0.58% | 5.89% | 0.41% | 6.82% | 7.65% | 5.99% |
| | 4 | 0.80% | 8.45% | 0.57% | 9.70% | 10.68% | 8.72% |
| | 5 | 0.96% | 10.72% | 0.98% | 12.44% | 13.53% | 11.35% |
| | 6 | 1.32% | 13.29% | 1.28% | 15.53% | 16.73% | 14.33% |
| | 7 | 1.66% | 15.18% | 1.55% | 17.88% | 19.15% | 16.61% |
| | 8 | 1.94% | 17.36% | 1.90% | 20.50% | 21.83% | 19.16% |
| | 9 | 2.30% | 18.71% | 2.36% | 22.45% | 23.83% | 21.07% |
| | 10 | 2.52% | 20.37% | 2.91% | 24.64% | 26.07% | 23.21% |
| | 11 | 2.78% | 21.51% | 3.33% | 26.23% | 27.69% | 24.77% |
| | 12 | 3.01% | 22.19% | 3.59% | 27.24% | 28.72% | 25.76% |
| CHILDREN | 13 | 3.32% | 22.84% | 3.86% | 28.28% | 29.78% | 26.79% |
| | 14 | 3.67% | 23.46% | 3.98% | 29.21% | 30.72% | 27.70% |
| | 15 | 4.19% | 24.63% | 4.22% | 30.84% | 32.37% | 29.30% |
| | 16 | 4.92% | 25.49% | 4.55% | 32.38% | 33.93% | 30.82% |
| | 17 | 5.50% | 26.23% | 5.00% | 33.78% | 35.35% | 32.21% |
| | 18 | 6.60% | 26.86% | 5.30% | 35.31% | 36.89% | 33.72% |
| | 19 | 7.86% | 27.34% | 5.48% | 36.72% | 38.33% | 35.12% |
| | 20 | 9.22% | 27.71% | 5.67% | 38.10% | 39.72% | 36.48% |
| | 21 | 10.08% | 28.14% | 5.90% | 39.19% | 40.83% | 37.55% |
| | 22 | 11.20% | 28.64% | 6.12% | 40.51% | 42.19% | 38.84% |
| | 23 | 11.95% | 28.82% | 6.23% | 41.23% | 42.19% | 39.51% |
| | 24 | 13.03% | 29.26% | 6.42% | 42.43% | 44.26% | 40.60% |
| | 25 | | | 0.42 % N/A | 42.43 % N/A | | 40.60 % N/A |
| | 20 | N/A | N/A | IN/A | IN/A | N/A | IN/A |

CONTACT US

This report is intended to provide both professionals and our CI wearers with relevant information on the reliability of our products. If you have any questions, please contact us by emailing hear@AdvancedBionics.com or visit AdvancedBionics.com for more general information.



■ ADVANCED BIONICS LLC – 28515 Westinghouse Place - Valencia, CA 91355, United States T: +1.877.829.0026 - T: +1.661.362.1400 - F: +1.661.362.1500 info.us@advancedbionics.com

EC REP ADVANCED BIONICS GMBH - Feodor-Lynen-Strasse 35 – 30625 Hannover, Germany

For information on additional AB locations, please visit advancedbionics.com/contact

Advanced Bionics - A Sonova brand

Please contact your local AB representative for regulatory approval and availability in your region.

